Glycemic Management in Patients with Coronary Artery Disease and Prediabetes or Type 2 Diabetes Mellitus

Overview

Journal Circulation

Specialty Cardiology & Vascular Diseases

Date 2014 Jun 18

PMID 24934464

Citations 7

Authors

Allison B Goldfine

Eng-Joo Phua

Martin J Abrahamson

Affiliations

Soon will be listed here.

Citing Articles

Nomogram for Predicting Hypoglycemia in Type 2 Diabetes Mellitus Patients Treated with Insulin Pump During Enteral Nutrition.

Wu J, Wu J, Zhou Y, Lu X, Zhao W, Xu F Diabetes Metab Syndr Obes. 2024; 17:2147-2154.

PMID: 38827166 PMC: 11141570. DOI: 10.2147/DMSO.S436390.

MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.

Szydelko J, Matyjaszek-Matuszek B Int J Mol Sci. 2023; 24(1).

PMID: 36614057 PMC: 9820734. DOI: 10.3390/ijms24010616.

The Effect of Female Sex on Short-Term Outcomes of Patients Undergoing Off-Pump Versus On-Pump Coronary Artery Bypass Grafting.

Fan J, Luo S, Pan Y, Wu T, Chen Y, Li W Braz J Cardiovasc Surg. 2022; 38(1):110-123.

PMID: 35895983 PMC: 10010711. DOI: 10.21470/1678-9741-2021-0301.

Single Nucleotide Polymorphism in the Chemerin Encoding Gene: Is It a Predictor of Insulin Resistance and Severity of Coronary Artery Disease in Non-Obese Type 2 Diabetes?.

Perumalsamy S, Wan Ahmad W, Huri H Healthcare (Basel). 2021; 9(6).

PMID: 34071097 PMC: 8224754. DOI: 10.3390/healthcare9060623.

Non-culprit plaque characteristics in acute coronary syndrome patients with raised hemoglobinA1c: an intravascular optical coherence tomography study.

Zhang S, Dai J, Jia H, Hu S, Du H, Li N Cardiovasc Diabetol. 2018; 17(1):90.

PMID: 29907160 PMC: 6002985. DOI: 10.1186/s12933-018-0729-5.

References

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch I, Inzucchi S, Genuth S . Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011; 154(8):554-9. DOI: 10.7326/0003-4819-154-8-201104190-00007. View

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

White W, Cannon C, Heller S, Nissen S, Bergenstal R, Bakris G . Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327-35. DOI: 10.1056/NEJMoa1305889. View

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

Knowler W, Fowler S, Hamman R, Christophi C, Hoffman H, Brenneman A . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374(9702):1677-86. PMC: 3135022. DOI: 10.1016/S0140-6736(09)61457-4. View

Gerstein H, Bosch J, Dagenais G, Diaz R, Jung H, Maggioni A . Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367(4):319-28. DOI: 10.1056/NEJMoa1203858. View

Monami M, Ahren B, Dicembrini I, Mannucci E . Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2012; 15(2):112-20. DOI: 10.1111/dom.12000. View

Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716):735-42. DOI: 10.1016/S0140-6736(09)61965-6. View

. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012; 35(4):723-30. PMC: 3308273. DOI: 10.2337/dc11-1468. View

10.

Monami M, Cremasco F, Lamanna C, Colombi C, Desideri C, Iacomelli I . Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011; 2011:215764. PMC: 3092497. DOI: 10.1155/2011/215764. View

11.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

12.

DeFronzo R, Tripathy D, Schwenke D, Banerji M, Bray G, Buchanan T . Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364(12):1104-15. DOI: 10.1056/NEJMoa1010949. View

13.

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

14.

Riddle M, Ambrosius W, Brillon D, Buse J, Byington R, Cohen R . Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010; 33(5):983-90. PMC: 2858202. DOI: 10.2337/dc09-1278. View

15.

Lipska K, Bailey C, Inzucchi S . Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34(6):1431-7. PMC: 3114336. DOI: 10.2337/dc10-2361. View

16.

Ban K, Hui S, Drucker D, Husain M . Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens. 2010; 3(4):245-59. DOI: 10.1016/j.jash.2009.04.001. View

17.

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

18.

Terzic A, Jahangir A, Kurachi Y . Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Am J Physiol. 1995; 269(3 Pt 1):C525-45. DOI: 10.1152/ajpcell.1995.269.3.C525. View

19.

Ray K, Seshasai S, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D . Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009; 373(9677):1765-72. DOI: 10.1016/S0140-6736(09)60697-8. View